Skip to content
type1.science

FreeStyle Libre 3 Plus

Abbott

Abbott's flagship sensor: the world's smallest and thinnest CGM, factory- calibrated, with 15-day wear and real-time minute-by-minute readings. An iCGM that now drives most of the mainstream US AID systems, Omnipod 5 included. It has replaced the original Libre 3 — but a 2025–26 Class I recall of sensors from one production line that could read falsely low is a live caveat.

Available nowRegulator-approvedcgm

The scorecard

Accuracy70

Headline accuracy is excellent — 15-day MARD 8.2% (adults) / 8.1% (children 6–17), strong in the hypo range. We score it well below that because sensors from one production line could read LOWER than actual glucose, and the FDA classified Abbott's November 2025 correction as a Class I recall — its most serious — on 4 February 2026, with 860 serious injuries and 7 deaths reported as of 7 January 2026. A separate FDA warning letter (23 January 2026) faulted Abbott for releasing finished sensors without accuracy-testing them after final assembly. Abbott says the cause is found and fixed and serial numbers are checkable at freestylecheck.com, but a spec-sheet MARD is not what people wore.[14]

Low lag65

Reads interstitial fluid, so the ~10-min physiological lag is inherent to the sensing category, not a Libre-specific flaw.[3]

Interoperability85

An iCGM that now drives four of the biggest US AID platforms — Omnipod 5 (US rollout from June 2026), the iLet, Tandem t:slim X2 (Control-IQ+) and twiist — closing most of the gap to Dexcom; still thin on open-source loop support.[12]

Sensor lifespan85

Up to 15-day wear — the longest of the mainstream patch CGMs.[1]

No calibration95

Factory-calibrated; no fingerstick calibration required.[6]

Alerts & prediction80

Streams a reading every minute to the phone with optional configurable high/low alarms; predictive alerting is less extensive than some rivals.[4]

Form factor92

World's smallest and thinnest sensor (about two stacked pennies), one-piece applicator, 60-minute warm-up.[4]

Ketone sensing0

No ketone sensing — glucose only. (Abbott has a dual glucose-ketone sensor in development, tracked separately.)

Access & cost80

Reimbursed in 37+ countries, historically lower-cost than rivals, and available via pharmacy pay-as-you-go; a major access advantage.[4]

The full picture

The FreeStyle Libre 3 Plus is Abbott's flagship continuous glucose monitor (CGM) — a small, round sensor you wear on the back of your upper arm that reads the glucose in the fluid just under your skin and sends a new value to your phone (or the Libre 3 reader) automatically every minute.1 It is factory-calibrated, so there are no fingerstick calibrations to do.2 It replaces the original Libre 3: in the UK the older sensor is being phased out by the end of March 2026, and the Plus is what new and existing users move to.3

Accuracy. In Abbott's pivotal study the 15-day sensor had a mean absolute relative difference (MARD — lower is better) of 8.2% in adults and 8.1% in children aged 6–17.4 The original Libre 3 was the first CGM to post a sub-8% MARD (7.9%),5 and in an independent head-to-head it was more accurate than the Dexcom G7 (8.9% vs 13.6%).6 Reassuringly, it holds up in the low range, with roughly 97–98% of readings within ±15 mg/dL of the lab reference in the hypo zone.4 As with every current sensor, it reads interstitial fluid, so there is a short (~10-minute) physiological lag and accuracy can dip during fast changes such as exercise.7

A Class I recall you should know about. On 24 November 2025 Abbott began a voluntary correction after its own testing found that some Libre 3 and Libre 3 Plus sensors from a single production line could report glucose values lower than the true value — the dangerous direction, because it can prompt someone to treat a low that isn't there, or to under-treat a high. The FDA issued an early alert on 1 December 2025 and, on 4 February 2026, classified the correction as a Class I recall, its most serious category.8 Roughly 3 million affected sensors had been distributed in the US from that line (about half of them already used or expired by then).9 As of 7 January 2026 Abbott had reported 860 serious injuries and 7 deaths potentially associated with the problem; in Abbott's November announcement the deaths were reported as having occurred outside the US.109 Libre 3 readers and apps, and every other Libre product (Libre 14 day, Libre 2, Libre 2 Plus, Libre Pro), are not affected.9 Abbott says the root cause has been identified and resolved, replaces affected sensors free of charge, and lets you check a sensor's serial number at freestylecheck.com.8 Separately, the FDA issued Abbott a warning letter dated 23 January 2026, following an October 2025 inspection of its Alameda, California site, faulting the company for releasing finished Libre CGMs without accuracy-testing them after final assembly, sterilisation and programming — testing had been done only on unassembled sensor parts.11 Practically: this is a manufacturing-lot problem, not a design flaw in the sensor technology, but it is a real one, and it is why this record scores accuracy lower than the headline MARD alone would suggest. If a reading does not match how you feel, confirm with a fingerstick.

Wear, warm-up, calibration. Up to 15 days per sensor — the longest of the mainstream patch CGMs — with a 60-minute warm-up and no calibration.2 It is water-resistant to 1 m for up to 30 minutes.2

Alerts. Readings stream to the phone every minute, with optional, configurable high and low glucose alarms.5

What it works with. The Libre 3 Plus is an iCGM (an interoperable CGM cleared to feed automated systems) for ages 2 and up.12 It now drives four automated insulin delivery (AID) systems: Insulet's Omnipod 5 — the highest-volume AID system in the US, which began its US rollout with the Libre 3 Plus on 3 June 2026 alongside an enhanced algorithm that adds a 100 mg/dL (5.6 mmol/L) glucose target option;13 the Beta Bionics iLet (the first US system to connect to it);14 the Tandem t:slim X2 with Control-IQ+;15 and Sequel's Tidepool-powered twiist.16 That is most of the mainstream US AID market, and it closes most of the ecosystem gap to Dexcom. It pairs with the FreeStyle Libre 3/3 Plus app on compatible iPhones and Android phones, plus LibreLinkUp for caregivers and LibreView for clinicians.2 Support in open-source DIY loops is still limited compared with Dexcom.

Ketones. None — this sensor measures glucose only. (Abbott has a separate dual glucose-ketone sensor in development, tracked elsewhere on this site.)

Who it's for, access, and cost. Indicated for people with diabetes aged 2 and older.12 Abbott's Libre platform is reimbursed in 37+ countries — including the US, UK, EU markets, Canada, Japan and Australia — and is positioned as a lower-cost option, historically around a third the price of some rivals, available via pharmacy pay-as-you-go.5 In the UK it is supplied on the NHS.3

What's coming. The bigger AID ecosystem is the near-term story: Insulet says international rollouts of Omnipod 5 with the Libre 3 Plus are planned for later in 2026,13 and t:slim X2 + Libre 3 Plus is rolling out internationally through 2026.15 The frontier feature for the Libre line is dual glucose-and-ketone sensing, which Abbott has in development.

References

  1. Abbott. Meet the FreeStyle Libre 3 Plus sensor. Abbott (n.d.). https://www.freestyle.abbott/us-en/products/freestyle-libre-3.html ↩

  2. Abbott. Meet the FreeStyle Libre 3 Plus sensor. Abbott (n.d.). https://www.freestyle.abbott/us-en/products/freestyle-libre-3.html ↩ ↩2 ↩3 ↩4

  3. Diabetes UK. FreeStyle Libre 3 sensors will be phased out and replaced with FreeStyle Libre 3 Plus. Diabetes UK (2025). https://www.diabetes.org.uk/about-us/news-and-views/freestyle-libre-3-sensors-will-be-phased-out-replaced-freestyle-libre-3-plus ↩ ↩2

  4. Alva S, et al. Accuracy of a 15-day Factory-Calibrated Continuous Glucose Monitoring System With Improved Sensor Design. J Diabetes Sci Technol (2025). PMID 40183340. https://pmc.ncbi.nlm.nih.gov/articles/PMC11977615/ ↩ ↩2

  5. Abbott. Abbott's FreeStyle Libre 3 Receives U.S. FDA Clearance — World's Smallest, Thinnest and Most Accurate 14-Day Glucose Sensor. PR Newswire (2022). https://www.prnewswire.com/news-releases/abbotts-freestyle-libre-3-receives-us-fda-clearance--features-worlds-smallest-thinnest-and-most-accurate-14-day-glucose-sensor-301557561.html ↩ ↩2 ↩3

  6. Hanson K, Kipnes M, Tran H. Comparison of Point Accuracy Between Two Widely Used Continuous Glucose Monitoring Systems. J Diabetes Sci Technol (2024). PMID 38189290. https://pmc.ncbi.nlm.nih.gov/articles/PMC11089878/ ↩

  7. Maytham K, et al. Accuracy of continuous glucose monitoring during exercise-related hypoglycemia in individuals with type 1 diabetes. Front Endocrinol (Lausanne) (2024). PMID 38686202. https://pmc.ncbi.nlm.nih.gov/articles/PMC11057372/ ↩

  8. U.S. Food and Drug Administration. Glucose Monitor Sensor Recall: Abbott Diabetes Care Removes Certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus Sensors. FDA (4 February 2026). https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/glucose-monitor-sensor-recall-abbott-diabetes-care-removes-certain-freestyle-libre-3-and-freestyle ↩ ↩2

  9. Abbott / U.S. Food and Drug Administration. Abbott Initiates Medical Device Correction for Certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus Sensors. FDA (24 November 2025). https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/abbott-initiates-medical-device-correction-certain-freestyle-librer-3-and-freestyle-libre-3-plus ↩ ↩2 ↩3

  10. American Hospital Association. FDA issues most serious recall for certain glucose monitor sensors. AHA News (4 February 2026). https://www.aha.org/news/headline/2026-02-04-fda-issues-most-serious-recall-certain-glucose-monitor-sensors ↩

  11. MedTech Dive. Abbott receives FDA warning letter over FreeStyle Libre CGMs. MedTech Dive (2026). https://www.medtechdive.com/news/abbott-receives-fda-warning-letter-over-freestyle-libre-cgms/811262/ ↩

  12. U.S. Food and Drug Administration. 510(k) K233537 — FreeStyle Libre 3 Continuous Glucose Monitoring System. FDA (2024). https://www.accessdata.fda.gov/cdrh_docs/pdf23/K233537.pdf ↩ ↩2

  13. Insulet. Insulet Announces U.S. Rollout of Enhanced Omnipod 5 Algorithm and Expands Compatibility with Abbott's FreeStyle Libre 3 Plus Sensor. Insulet Investor Relations (3 June 2026). https://investor.insulet.com/news/news-details/2026/Insulet-Announces-U-S--Rollout-of-Enhanced-Omnipod-5-Algorithm-and-Expands-Compatibility-with-Abbotts-FreeStyle-Libre-3-Plus-Sensor/default.aspx ↩ ↩2

  14. Beta Bionics. Beta Bionics Launches the iLet Bionic Pancreas With Abbott's FreeStyle Libre 3 Plus Sensor. Drug Delivery Business News (2024). https://www.drugdeliverybusiness.com/beta-bionics-launches-ilet-abbott-libre/ ↩

  15. Tandem Diabetes Care. t:slim X2 Insulin Pump Now Available With Abbott's FreeStyle Libre 3 Plus Sensor in the United States. HIT Consultant (2025). https://hitconsultant.net/2025/10/30/tandem-diabetes-care-launches-tslim-x2-pump-integration-with-abbott-freestyle-libre-3-plus/ ↩ ↩2

  16. Sequel Med Tech. Sequel Announces First CGM Integration for its twiist AID System: Abbott's FreeStyle Libre 3 Plus Sensor. GlobeNewswire (2025). https://www.globenewswire.com/news-release/2025/03/18/3044465/0/en/Sequel-Announces-First-CGM-Integration-for-its-twiist-AID-System-Abbott-s-FreeStyle-Libre-3-Plus-Sensor.html ↩

What's next for this

  • →International rollout of Omnipod 5 + Libre 3 Plus · later in 2026
  • →Tandem t:slim X2 + Libre 3 Plus integration rolling out internationally · through 2026
  • →Dual glucose-and-ketone sensing in development for the Libre line

Sources

  1. [1]Accuracy of a 15-day Factory-Calibrated Continuous Glucose Monitoring System With Improved Sensor Design · peer-reviewed · 2025-04-04 — Alva et al., J Diabetes Sci Technol. Pivotal accuracy study covering the Libre 2 Plus and Libre 3 Plus sensors (PMID 40183340, DOI 10.1177/19322968251329364).
  2. [2]Comparison of Point Accuracy Between Two Widely Used Continuous Glucose Monitoring Systems · peer-reviewed · 2024-01-08 — Hanson, Kipnes & Tran, J Diabetes Sci Technol. Head-to-head Libre 3 vs Dexcom G7 (PMID 38189290, DOI 10.1177/19322968231225676).
  3. [3]Accuracy of continuous glucose monitoring during exercise-related hypoglycemia in individuals with type 1 diabetes · peer-reviewed · 2024-04-15 — Maytham et al., Front Endocrinol. Illustrates interstitial-lag and hypo-range accuracy issues common to current CGMs (PMID 38686202, DOI 10.3389/fendo.2024.1352829).
  4. [4]Abbott's FreeStyle Libre 3 Receives U.S. FDA Clearance — World's Smallest, Thinnest and Most Accurate 14-Day Glucose Sensor · manufacturer · 2022-05-31 — Abbott press release — form factor, minute-by-minute readings, sub-8% MARD, optional alarms, low relative cost.
  5. [5]FDA 510(k) K233537 — FreeStyle Libre 3 Continuous Glucose Monitoring System (age 2 and older) · regulatory · 2024-04-23 — FDA clearance document confirming the iCGM indication for persons age 2 and older.
  6. [6]Meet the FreeStyle Libre 3 Plus sensor · manufacturer — Abbott product page — 15-day wear, 60-minute warm-up, age 2+, factory calibration, water resistance, every-minute readings, compatible apps.
  7. [7]FreeStyle Libre 3 sensors will be phased out and replaced with FreeStyle Libre 3 Plus · news — Diabetes UK — confirms the Plus replaces the original Libre 3, with a UK phase-out by end of March 2026 and NHS availability.
  8. [8]FreeStyle Libre 3 and FreeStyle Libre 3 Plus · news — American Diabetes Association Consumer Guide — wear days, warm-up, age ranges, MARD, and pump compatibility (iLet, t:slim X2, twiist).
  9. [9]Sequel Announces First CGM Integration for its twiist AID System — Abbott's FreeStyle Libre 3 Plus Sensor · manufacturer · 2025-03-18 — Sequel Med Tech press release — Libre 3 Plus as the first CGM for the Tidepool-powered twiist AID system.
  10. [10]Beta Bionics Launches the iLet Bionic Pancreas With Abbott's FreeStyle Libre 3 Plus Sensor · manufacturer · 2024-10-30 — First U.S. insulin-delivery system to connect to the Libre 3 Plus; users can choose Libre 3 Plus or Dexcom.
  11. [11]t:slim X2 Insulin Pump Now Available With Abbott's FreeStyle Libre 3 Plus Sensor in the United States · manufacturer · 2025-10-29 — Tandem t:slim X2 with Control-IQ+ AID now integrates the Libre 3 Plus in the US; international rollout planned for 2026.
  12. [12]Insulet Announces U.S. Rollout of Enhanced Omnipod 5 Algorithm and Expands Compatibility with Abbott's FreeStyle Libre 3 Plus Sensor · manufacturer · 2026-06-03 — Insulet press release — US rollout of Omnipod 5 with the Libre 3 Plus (following a December 2025 FDA 510(k) for the enhanced algorithm), a new 100 mg/dL (5.6 mmol/L) target option, caregiver following via LibreLinkUp, and further international rollouts planned for later in 2026.
  13. [13]Abbott Initiates Medical Device Correction for Certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus Sensors · regulatory · 2025-11-24 — Abbott's announcement as hosted by the FDA — sensors from a single production line may report falsely low glucose; roughly 3 million US sensors affected; other Libre products are not affected.
  14. [14]Glucose Monitor Sensor Recall: Abbott Diabetes Care Removes Certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus Sensors · regulatory · 2026-02-04 — FDA classified Abbott's November 2025 correction as Class I (most serious) on 4 February 2026; free replacement sensors, serial-number check at freestylecheck.com.
  15. [15]FDA issues most serious recall for certain glucose monitor sensors · news · 2026-02-04 — American Hospital Association — confirms the Class I classification and Abbott's report of 860 serious injuries and 7 deaths as of 7 January 2026.
  16. [16]Abbott receives FDA warning letter over FreeStyle Libre CGMs · news · 2026-02-03 — MedTech Dive — FDA warning letter dated 23 January 2026, after an October 2025 inspection of Abbott's Alameda, CA site, citing release of finished Libre CGMs without accuracy testing after final assembly.